Skip to main content

ABC News: FDA approves drug for heart failure that may keep patients out of the hospital during the COVID-19 pandemic

May 8, 2020

AstraZeneca's diabetes drug, Farxiga, has become the first in its class to receive FDA approval as a treatment for heart failure.

ABC News talked to Dr. Mikhail Kosiborod, cardiologist at Saint Luke's Mid America Heart Institute and vice president of research at Saint Luke's, who investigated the drug before its approval.

AstraZeneca is also studying whether the drug may benefit certain patients with COVID-19—some who suffer from mysterious problems like blood clots and heart damage.

Read the full ABC News article: FDA approves drug for heart failure that may keep patients out of the hospital during the COVID-19 pandemic

Related Content

COVID-19 (Coronavirus): What You Need to Know
The latest information on staying safe and healthy and how Saint Luke's is preparing for COVID-19 in the Kansas City community.
KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's
KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's
As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in Kansas City.
Blue sphere COVID-19 viruses
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in COVID-19 patients.